{"product_id":"penn-medicine-new-horizons-in-nephrology-glomerular-disease-webinar-2026","title":"Penn Medicine New Horizons in Nephrology Glomerular Disease Webinar 2026","description":"\u003ch1 class=\"product_title entry-title\"\u003ePenn Medicine New Horizons in Nephrology Glomerular Disease Webinar 2026\u003c\/h1\u003e\r\n\u003cspan style=\"font-size: 23.04px; color: #333333;\"\u003e1. Overview\u003c\/span\u003e\r\n\u003cdiv class=\"container\"\u003e\r\n\u003cdiv id=\"model-response-message-contentr_604f42131eb8a27c\" class=\"markdown markdown-main-panel enable-updated-hr-color\" dir=\"ltr\" aria-live=\"polite\" aria-busy=\"false\"\u003e\r\n\u003cp data-path-to-node=\"1\"\u003eThe Penn Medicine New Horizons in Nephrology Glomerular Disease Webinar 2026 provides a focused, expert-led clinical update on the pathophysiology and modern management of complex glomerular diseases. The program heavily emphasizes the role of the B-cell pathway, featuring specific targeting strategies and case-based applications for conditions such as IgA nephropathy, lupus nephritis, and membranous nephropathy.\u003c\/p\u003e\r\n\u003cp data-path-to-node=\"1\"\u003eB cells play a central role in the pathogenesis of many glomerular diseases through antibody production, antigen presentation, and cytokine release that drive renal inflammation and injury. Diseases such as lupus nephritis, membranous nephropathy, IgA nephropathy, and ANCA-associated vasculitis are characterized by pathogenic autoantibodies or immune complex deposition, underscoring B cells as key therapeutic targets. Advances in our understanding of B-cell biology have led to the development of novel treatment strategies, including monoclonal antibodies targeting CD20 (rituximab, obinutuzumab), CD19, and BAFF\/APRIL signaling pathways. These therapies aim to modulate B-cell activity, reduce pathogenic antibody production, and achieve sustained disease remission with fewer side effects compared to traditional immunosuppression. Given the rapidly expanding landscape of B-cell–directed therapies and their emerging indications in glomerular diseases, it is critical for clinicians to understand their mechanisms, efficacy data, and safety considerations to optimize patient outcomes.\u003c\/p\u003e\r\n\u003cp data-path-to-node=\"1\"\u003e\u003cb data-path-to-node=\"1\" data-index-in-node=\"417\"\u003eCourse Date:\u003c\/b\u003e Thursday, February 26, 2026, 5:00 PM – 8:00 PM\u003c\/p\u003e\r\n\r\n\u003ch2 data-path-to-node=\"2\"\u003e2. Learning Objectives\u003c\/h2\u003e\r\n\u003cul data-path-to-node=\"3\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,0,0\"\u003eAnalyze the underlying physiology and monitoring strategies of the B-cell pathway in the context of glomerular diseases.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,1,0\"\u003eEvaluate the clinical efficacy and application of B-cell targeting therapies in the management of IgA Nephropathy.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,2,0\"\u003eImplement updated, evidence-based B-cell targeting protocols for the treatment of Lupus Nephritis.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,3,0\"\u003eAssess novel therapeutic approaches and targeted interventions for Membranous Nephropathy and Primary Podocytopathy.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,4,0\"\u003eApply advanced diagnostic and therapeutic strategies to real-world clinical scenarios through expert-led case presentations.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-path-to-node=\"4\"\u003e3. Target Audience\u003c\/h2\u003e\r\n\u003cdiv\u003eSpecialties – INTERNAL MEDICINE – Nephrology\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv\u003eBest for nephrologists and internal medicine physicians who want updates on B-cell targeted therapies and glomerular disease management.\u003c\/div\u003e\r\n\u003ch2 data-path-to-node=\"6\"\u003e4. Topics\u003c\/h2\u003e\r\n\u003col start=\"1\" data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003eAsk the Panel – 01\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003eAsk the Panel\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003eB-cell Targeting in IgA Nephropathy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003eB-cell Targeting in Lupus Nephritis\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003eB-cell Targeting in Membranous Nephropathy, Primary Podocytopathy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003eCase Presentation 1- Membranous Nephropathy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003eCase Presentation 2- Lupus Nephritis\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003eCase presentation 3- IgA Nephropathy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,8,0\"\u003ePhysiology, Monitoring and Targeting the B-Cell Pathway\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954682826850,"sku":"MED-AMB08112","price":15.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Penn-Medicine-New-Horizons-in-Nephrology-Glomerular-Disease-Webinar-2026.jpg?v=1779382364","url":"https:\/\/meducourse.com\/products\/penn-medicine-new-horizons-in-nephrology-glomerular-disease-webinar-2026","provider":"Meducourse","version":"1.0","type":"link"}